http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 16:15:43 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/AtriCure+%28ATRC%29+Tops+Q2+EPS+by+19c%2C+Beats+on+Revenue%3B+Offers+FY26+EPS+Guidance/26808278.html <p>AtriCure (NASDAQ: ATRC) reported Q2 EPS of $0.18, $0.19 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $153.6 million versus the consensus estimate of $151.84 million.</p><p><strong>GUIDANCE:</strong></p><p>AtriCure sees FY2026 EPS of $0.24-$0.32, versus the consensus of $0.12.</p><p>For earnings history and earnings-related data on AtriCure (ATRC) <a href="http://www.streetinsider.com/ec_earnings.php?q=ATRC">click here</a>.</p> http://www.streetinsider.com/Earnings/AtriCure+%28ATRC%29+Tops+Q2+EPS+by+19c%2C+Beats+on+Revenue%3B+Offers+FY26+EPS+Guidance/26808278.html Thu, 23 Jul 2026 16:15:43 -0400 ATRC http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Press+Releases/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html <ul class="bwlistdisc"> <li> Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year </li> <li> Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million </li> <li> Second Quarter 2026 cash generation of $21.6 million </li> </ul> <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=8341ed45278f9fca9e37215a7b2de41d" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54576000&amp;newsitemid=20260723794845&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=eaca374e15484bc9ea5c7af61c284919" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. </p><p> “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said http://www.streetinsider.com/Business+Wire/AtriCure+Reports+Second+Quarter+2026+Financial+Results/26807852.html Thu, 23 Jul 2026 16:01:00 -0400 A.14757992 ATRC O.00765647 O.06166724 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jul+23/26807835.html si-local-file:///var/storage/secattach/20260723/26807835.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jul+23/26807835.html Thu, 23 Jul 2026 16:00:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jul+23/26807835.html si-local-file:///var/storage/secattach/20260723/26807835.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jul+23/26807835.html Thu, 23 Jul 2026 16:00:00 -0400 ATRC O.00765647 http://www.streetinsider.com/Analyst+Comments/AtriCure+%28ATRC%29+Reiterated+at+Market+Outperform+by+Citizens+on+Consistent+Product+Iteration/26791153.html <p>Citizens analyst Daniel Stauder reiterated a Market Outperform rating and $52.00 price target on AtriCure Inc. (NASDAQ: ATRC).</p><p>The analyst commented, "We reiterate our Market Outperform rating and $52 price target on shares of AtriCure. Our model calls for +11% y/y sales growth on the company's toughest FY26 prior year comp, led by its Pain Management, Open Ablation, and AtriClip franchises. AtriCure's consistent low double-digit top-line improvement continues to be driven by its product launches which have had notably long-tails of growth —including its Encompass clamp, CryoSPHERE MAX, and AtriClip Flex-MINI devices. We expect 2Q26 and 2H26 to continue to reflect http://www.streetinsider.com/Analyst+Comments/AtriCure+%28ATRC%29+Reiterated+at+Market+Outperform+by+Citizens+on+Consistent+Product+Iteration/26791153.html Tue, 21 Jul 2026 04:47:59 -0400 ATRC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+CARREL+MICHAEL+H/26724760.html si-local-file:///var/storage/secattach/20260702/26724760.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+CARREL+MICHAEL+H/26724760.html Thu, 02 Jul 2026 09:06:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+CARREL+MICHAEL+H/26724760.html si-local-file:///var/storage/secattach/20260702/26724760.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+CARREL+MICHAEL+H/26724760.html Thu, 02 Jul 2026 09:06:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Doraiswamy+Vinayak/26724755.html si-local-file:///var/storage/secattach/20260702/26724755.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Doraiswamy+Vinayak/26724755.html Thu, 02 Jul 2026 09:05:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Doraiswamy+Vinayak/26724755.html si-local-file:///var/storage/secattach/20260702/26724755.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Doraiswamy+Vinayak/26724755.html Thu, 02 Jul 2026 09:05:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Dahlquist+Karl+S./26724738.html si-local-file:///var/storage/secattach/20260702/26724738.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Dahlquist+Karl+S./26724738.html Thu, 02 Jul 2026 09:04:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Dahlquist+Karl+S./26724738.html si-local-file:///var/storage/secattach/20260702/26724738.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Dahlquist+Karl+S./26724738.html Thu, 02 Jul 2026 09:04:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Seith+Douglas+J/26724700.html si-local-file:///var/storage/secattach/20260702/26724700.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Seith+Douglas+J/26724700.html Thu, 02 Jul 2026 09:00:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Seith+Douglas+J/26724700.html si-local-file:///var/storage/secattach/20260702/26724700.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Seith+Douglas+J/26724700.html Thu, 02 Jul 2026 09:00:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Privitera+Salvatore/26724602.html si-local-file:///var/storage/secattach/20260702/26724602.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Privitera+Salvatore/26724602.html Thu, 02 Jul 2026 08:58:00 -0400 ATRC O.00765647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Privitera+Salvatore/26724602.html si-local-file:///var/storage/secattach/20260702/26724602.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AtriCure%2C+Inc.++++++++++++For%3A+Jun+30++Filed+by%3A+Privitera+Salvatore/26724602.html Thu, 02 Jul 2026 08:58:00 -0400 ATRC O.00765647 http://www.streetinsider.com/Press+Releases/AtriCure+to+Announce+Second+Quarter+2026+Financial+Results/26724148.html <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Atricure.com&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=2b3bbf316238bf987823845e5389f5d3" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=dc085a4c4d9f45c1a69dfc31d2227aef" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. </p><p> AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listening to the conference call should <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fenymkif7&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=register+online+using+this+link&amp;index=3&amp;md5=4a28a1ccdbf7a8c6e941257b0e41ba5d" shape="rect">register online using this link</a>. Participants are encouraged to http://www.streetinsider.com/Press+Releases/AtriCure+to+Announce+Second+Quarter+2026+Financial+Results/26724148.html Thu, 02 Jul 2026 08:00:00 -0400 ATRC O.00765647 http://www.streetinsider.com/Press+Releases/AtriCure+to+Announce+Second+Quarter+2026+Financial+Results/26724148.html <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Atricure.com&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=2b3bbf316238bf987823845e5389f5d3" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=dc085a4c4d9f45c1a69dfc31d2227aef" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. </p><p> AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listening to the conference call should <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fenymkif7&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=register+online+using+this+link&amp;index=3&amp;md5=4a28a1ccdbf7a8c6e941257b0e41ba5d" shape="rect">register online using this link</a>. Participants are encouraged to http://www.streetinsider.com/Press+Releases/AtriCure+to+Announce+Second+Quarter+2026+Financial+Results/26724148.html Thu, 02 Jul 2026 08:00:00 -0400 ATRC O.00765647 http://www.streetinsider.com/Business+Wire/AtriCure+to+Announce+Second+Quarter+2026+Financial+Results/26724148.html <p> MASON, Ohio--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Atricure.com&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=2b3bbf316238bf987823845e5389f5d3" shape="rect">AtriCure, Inc.</a> (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=Nasdaq%3A+ATRC&amp;index=2&amp;md5=dc085a4c4d9f45c1a69dfc31d2227aef" shape="rect">Nasdaq: ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. </p><p> AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listening to the conference call should <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fenymkif7&amp;esheet=54558101&amp;newsitemid=20260702970337&amp;lan=en-US&amp;anchor=register+online+using+this+link&amp;index=3&amp;md5=4a28a1ccdbf7a8c6e941257b0e41ba5d" shape="rect">register online using this link</a>. Participants are encouraged to http://www.streetinsider.com/Business+Wire/AtriCure+to+Announce+Second+Quarter+2026+Financial+Results/26724148.html Thu, 02 Jul 2026 08:00:00 -0400 ATRC O.00765647